{
    "clinical_study": {
        "@rank": "114409", 
        "arm_group": {
            "arm_group_label": "RX-3117", 
            "arm_group_type": "Experimental", 
            "description": "All subjects will receive RX-3117."
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine the maximum tolerated dose of RX-3117 in subjects\n      with advanced or metastatic solid tumors."
        }, 
        "brief_title": "Dose-Finding and Safety Study for Oral Single-Agent to Treat Advanced Malignancies", 
        "completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Solid Tumor", 
        "detailed_description": {
            "textblock": "This is a dose-finding, open-label, single agent study of RX-3117.  Subjects will be treated\n      for up to 8 cycles of therapy.  A cycle will be 4 weeks.  RX-3117 dosing will be 3 times\n      each week for 3 weeks follow by 1 week off treatment.  All subjects will be followed for at\n      least 30 days after the last dose of RX-3117."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Males or females who are 18 years or older\n\n          -  Able to swallow capsules\n\n          -  Histological or cytological evidence of confirmed solid tumor malignancy\n\n          -  Able to discontinue all anticancer therapies 2 weeks prior to study start\n\n          -  Measurable or evaluable disease using Response Evaluation Criteria in Solid Tumors\n\n          -  Life expectancy of at least 3 months\n\n          -  ECOG performance status of  0, 1 or 2\n\n          -  Provide written informed consent\n\n        Exclusion Criteria:\n\n          -  Primary brain tumors or clinical evidence of active brain metastasis\n\n          -  Systemic corticosteroid use within 7 days before planned start of study therapy\n\n          -  Active infection requiring parenteral or oral antibiotics within 2 weeks before\n             planned start of study therapy\n\n          -  Uncontrolled diabetes as assessed by the investigator\n\n          -  Prior or current history of hepatitis B, hepatitis C or human immunodeficiency virus\n\n          -  History of bone marrow of solid organ transplantation\n\n          -  History of congestive heart failure, arrhythmias, acute coronary syndrome or torsades\n             de pointes\n\n          -  Any other medical, psychiatric, or social condition, which in the opinion of the\n             investigator, would preclude participation in the study, pose an undue medical\n             hazard, interfere with the conduct of the study, or interfere with interpretation of\n             the study results\n\n          -  Known hypersensitivity to gemcitabine, azacytidine or cytosine arabinoside\n\n          -  Pregnant, planning a pregnancy or breast feeding during the study\n\n          -  Concurrent participation in another therapeutic clinical trial"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 24, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02030067", 
            "org_study_id": "RX-3117-P1-01"
        }, 
        "intervention": {
            "arm_group_label": "RX-3117", 
            "description": "escalating doses", 
            "intervention_name": "RX-3117", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "oncology", 
            "tumor", 
            "metastatic"
        ], 
        "lastchanged_date": "January 8, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "San Antonio", 
                    "country": "United States", 
                    "state": "Texas", 
                    "zip": "78229"
                }, 
                "name": "Rexahn Site"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 1, Open-Label, Dose-Ranging, Safety and Pharmacokinetic Study to Determine the Maximum Tolerated Dose of RX-3117 Administered Orally as a Single-Agent to Subjects With Advanced Malignancies", 
        "other_outcome": {
            "measure": "Biomarker concentrations in blood", 
            "safety_issue": "No", 
            "time_frame": "Baseline and 8, 16 and 32 weeks"
        }, 
        "overall_contact": {
            "email": "petersonc@rexahn.com", 
            "last_name": "Christine Peterson, PhD", 
            "phone": "240-268-5300", 
            "phone_ext": "320"
        }, 
        "overall_official": {
            "affiliation": "Rexahn Pharmaceuticals, Inc.", 
            "last_name": "Christine Peterson, PhD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Incidence of dose limiting toxicities", 
            "safety_issue": "Yes", 
            "time_frame": "4 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02030067"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Area under the plasma concentration time curve (AUC)", 
                "safety_issue": "No", 
                "time_frame": "pre-dose and at 0.5, 1, 2, 3, 4, 6, 8, 24 and 48 hours after oral administration in Cycle 1 Days 1 and 15"
            }, 
            {
                "measure": "Changes in tumor size", 
                "safety_issue": "No", 
                "time_frame": "Baseline and at 8, 16 and 32 weeks"
            }, 
            {
                "measure": "Cmax", 
                "safety_issue": "No", 
                "time_frame": "pre-dose and at 0.5, 1, 2, 3, 4, 6, 8, 24 and 48 hours after oral administration in Cycle 1 Days 1 and 15"
            }
        ], 
        "source": "Rexahn Pharmaceuticals, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Rexahn Pharmaceuticals, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}